Biomarkers crashed back to Earth this week as clinicians and regulatory specialists joined the usual crowd of academics and industry scientists for a sobering reality check at the IBC Biomarkers conference in Reston, Va. Speakers across the board warned of steep obstacles to bringing a validated, reproducible, effective, and FDA-approved proteomic biomarker test — diagnostic or otherwise — to the clinic, as they hashed out the nitty gritty details of sample collection and handling, statistical analysis, identification of spectrum peaks, and government regulations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.

A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.

The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.

In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.